腺氨酸A2A信号和 dystonia 的情况
1Department of Neurodegenerative disorders, Kansai Medical University, Hirakata, Osaka, Japan.
International review of neurobiology
|September 23, 2023
概括
氨酸A2A受体对抗性显示出治疗动作障碍 - - dystonia 的潜力. 这种方法,使用像伊斯特拉德菲林这样的药物,可以改善类似于晚期帕金森病症状的症状.
科学领域:
- 神经科学是一个神经科学.
- 运动障碍 运动障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 肌痛症涉及非自愿的肌肉收缩,通常在晚期帕金森病 (PD) 中被视为坎普托科尔米亚和皮萨综合征.
- 伊斯特拉迪菲林是一种腺A2A受体对抗剂,在PD中用于减少"关闭"时间,并且在改善坎普托科尔米亚方面表现出有效性.
研究的目的:
- 讨论腺A2A对抗作用对 dystonia 的潜在治疗效果.
- 探索氨酸A2A受体在基底腺电路中的作用,这与 dystonia 有关.
主要方法:
- 对PD与姿势异常和伊斯特拉德菲林的临床研究的综述.
- 检查了动物模型的dystonia的发现.
主要成果:
- 氨酸A2A受体在基底神经元和胆内神经元中发现,影响运动控制通路.
- 临床证据表明,伊斯特拉德菲林可以改善坎普托科尔米亚 (camptocormia),这种状况具有类似于 dystonia 的特征.
结论:
- 腺氨酸A2A对抗性为 dystonia 提供了一个有前途的治疗策略.
- 对腺A2A受体阻断的进一步研究可能为运动障碍提供新的治疗方法.
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
709
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
709
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.4K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
450
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
450
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.1K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
698
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
698


